Monte Rosa Therapeutics (Monte Rosa Therapeutics) EBIT per Share : $-2.69 (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Monte Rosa Therapeutics EBIT per Share?

Monte Rosa Therapeutics's EBIT per Share for the three months ended in Mar. 2024 was $-0.58. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.69.

During the past 3 years, the average EBIT per Share Growth Rate was -29.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Monte Rosa Therapeutics's EBIT per Share or its related term are showing as below:

GLUE' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -49.2 Med: -39.25 Max: -29.3
Current: -29.3

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Monte Rosa Therapeutics was -29.30% per year. The lowest was -49.20% per year. And the median was -39.25% per year.

GLUE's 3-Year EBIT Growth Rate is ranked worse than
81.61% of 1305 companies
in the Biotechnology industry
Industry Median: 3.4 vs GLUE: -29.30

Monte Rosa Therapeutics's EBIT for the three months ended in Mar. 2024 was $-34.95 Mil.

Monte Rosa Therapeutics EBIT per Share Historical Data

The historical data trend for Monte Rosa Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Monte Rosa Therapeutics EBIT per Share Chart

Monte Rosa Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-0.69

-1.29

-2.92

-2.38

-2.79

Monte Rosa Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial													-0.69	-0.75	-0.74	-0.61	-0.58

Monte Rosa Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Monte Rosa Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-143.311	/	51.397
=	-2.79

Monte Rosa Therapeutics's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-34.947	/	60.156
=	-0.58

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.69

Monte Rosa Therapeutics (NAS:GLUE) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Monte Rosa Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Monte Rosa Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Monte Rosa Therapeutics (Monte Rosa Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Monte Rosa Therapeutics Inc (NAS:GLUE) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

645 Summer Street, Suite 102, Boston, MA, USA, 02210

Website

https://www.monterosatx.com

Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates.

Executives

Edmund Dunn	officer: Principal Accounting Officer	MONTE ROSA THERAPEUTICS, INC., 321 HARRISON AVENUE, SUITE 900, BOSTON MA 02210
Anthony M. Manning	director	C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Jan Skvarka	director	C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9
Philip Nickson	officer: General Counsel	MONTE ROSA THERAPEUTICS, INC., 40 GUEST STREET, BOSTON MA 02135
Julian G Jones	officer: Chief Business Officer	MONTE ROSA THERAPEUTICS, INC., 645 SUMMER STREET, SUITE 102, BOSTON MA 02210
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Joshua Makower	10 percent owner	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Paul Edward Walker	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Versant Venture Capital Vi, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Edward T Mathers	10 percent owner	C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Kimberly Blackwell	director	C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Cormorant Private Healthcare Fund Ii, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
New Enterprise Associates 17, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 17, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093